BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34918174)

  • 1. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study.
    Liu QP; Yang KL; Xu X; Liu XS; Qu JR; Zhang YD
    Abdom Radiol (NY); 2022 Feb; 47(2):651-663. PubMed ID: 34918174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral and peritumoral radiomics based on contrast-enhanced MRI for preoperatively predicting treatment response of transarterial chemoembolization in hepatocellular carcinoma.
    Zhao Y; Zhang J; Wang N; Xu Q; Liu Y; Liu J; Zhang Q; Zhang X; Chen A; Chen L; Sheng L; Song Q; Wang F; Guo Y; Liu A
    BMC Cancer; 2023 Oct; 23(1):1026. PubMed ID: 37875815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.
    Shi ZX; Li CF; Zhao LF; Sun ZQ; Cui LM; Xin YJ; Wang DQ; Kang TR; Jiang HJ
    Hepatobiliary Pancreat Dis Int; 2024 Aug; 23(4):361-369. PubMed ID: 37429785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Analysis Using Albumin-Bilirubin (ALBI) Grade for Patients Treated with Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Young LB; Tabrizian P; Sung J; Biederman D; Bishay VL; Ranade M; Patel RS; Nowakowski FS; Fischman AM; Lookstein RA; Kim E
    J Vasc Interv Radiol; 2022 May; 33(5):510-517.e1. PubMed ID: 35150838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE.
    Kong C; Zhao Z; Chen W; Lv X; Shu G; Ye M; Song J; Ying X; Weng Q; Weng W; Fang S; Chen M; Tu J; Ji J
    Eur Radiol; 2021 Oct; 31(10):7500-7511. PubMed ID: 33860832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.
    Hansmann J; Evers MJ; Bui JT; Lokken RP; Lipnik AJ; Gaba RC; Ray CE
    J Vasc Interv Radiol; 2017 Sep; 28(9):1224-1231.e2. PubMed ID: 28688815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T1 relaxation time analysis in predicting hepatic dysfunction and prognosis in patients with HCC undergoing transarterial chemoembolization.
    Huang H; Qiao H; Jiang J; Yan J; Wen Q; Gen D; Wu Q
    Eur J Radiol; 2023 Aug; 165():110938. PubMed ID: 37392548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features.
    Liu J; Pei Y; Zhang Y; Wu Y; Liu F; Gu S
    Abdom Radiol (NY); 2021 Aug; 46(8):3748-3757. PubMed ID: 33386449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-institutional study to predict the benefits of DEB-TACE and molecular targeted agent sequential therapy in unresectable hepatocellular carcinoma using a radiological-clinical nomogram.
    Liu K; Zheng X; Lu D; Tan Y; Hou C; Dai J; Shi W; Jiang B; Yao Y; Lu Y; Cao Q; Chen R; Zhang W; Xie J; Chen L; Jiang M; Zhang Z; Liu L; Liu J; Li J; Lv W; Wu X
    Radiol Med; 2024 Jan; 129(1):14-28. PubMed ID: 37863847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MRI-Based Radiomics: Nomograms predicting the short-term response after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma patients with diameter less than 5 cm.
    Kuang Y; Li R; Jia P; Ye W; Zhou R; Zhu R; Wang J; Lin S; Pang P; Ji W
    Abdom Radiol (NY); 2021 Aug; 46(8):3772-3789. PubMed ID: 33713159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
    Abajian A; Murali N; Savic LJ; Laage-Gaupp FM; Nezami N; Duncan JS; Schlachter T; Lin M; Geschwind JF; Chapiro J
    J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
    Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
    BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
    J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics.
    Kim J; Choi SJ; Lee SH; Lee HY; Park H
    AJR Am J Roentgenol; 2018 Nov; 211(5):1026-1034. PubMed ID: 30240304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted imaging of hepatocellular carcinoma before and after transarterial chemoembolization: role in survival prediction and response evaluation.
    Labeur TA; Runge JH; Klompenhouwer EG; Klümpen HJ; Takkenberg RB; van Delden OM
    Abdom Radiol (NY); 2019 Aug; 44(8):2740-2750. PubMed ID: 31069479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the Outcome of Transcatheter Arterial Embolization Therapy for Unresectable Hepatocellular Carcinoma Based on Radiomics of Preoperative Multiparameter MRI.
    Sun Y; Bai H; Xia W; Wang D; Zhou B; Zhao X; Yang G; Xu L; Zhang W; Liu P; Xu J; Meng S; Liu R; Gao X
    J Magn Reson Imaging; 2020 Oct; 52(4):1083-1090. PubMed ID: 32233054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; An C; Sun HL; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Int J Hyperthermia; 2019; 36(1):841-853. PubMed ID: 31452408
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
    Niu XK; He XF
    World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.